The earliest phase of B cell development from stem cells proceeds in two steps: the commitment to common lymphoid progenitor cells and the subsequent differentiation of the common lymphoid progenitor cells to the earliest cells in the B-lineage pathway (pro-B) (7), defined as cells that express the B220 surface marker and give rise to B lineage but not T lineage cells (6). Pro-B can be divided into three stages [designated Fractions (Fr.) A, B, and C by Hardy and colleagues (2) In adult BM, the surface markers that distinguish pro-B cells from cells at later stages of B cell development include B220 levels, CD4, CD43, BP-1, CD24, IgM, IgD, and MHC class II (Ia). Of these, only B220 and CD4 are expressed on germ-line pro-B cells. B220 is expressed at low or intermediate levels on all of these cells, whereas CD4 is expressed on a major subset (which expresses B220 at intermediate levels). The ability of the CD4 ϩ subset to give rise to B cells has recently been brought into question by evidence showing that these cells fail to develop into B cells in vitro under conditions that readily allow B cell development from germ-line pro-B that do not express CD4 (9, 10). Studies here, however, show that both subsets express roughly equal amounts of mRNA encoding traditional pro-B cell markers-i.e., sterile , TdT, Ig␤ (CD79b)-and hence indicate that both subsets contain B cell progenitors.
B
cell development occurs in fetal and neonatal liver and in adult bone marrow (BM) by the orderly progression of B-lineage precursor cells through a series of genetically and phenotypically defined stages of differentiation (1) (2) (3) (4) (5) (6) (7) (8) . These stages (pre-pro-B, early pro-B, late pro-B, pre-B, immature B, and mature B cells) are each characterized by a distinct surface phenotype (8) and by the progressive status of Ig heavy and Ig light chain gene rearrangement and expression.
The earliest phase of B cell development from stem cells proceeds in two steps: the commitment to common lymphoid progenitor cells and the subsequent differentiation of the common lymphoid progenitor cells to the earliest cells in the B-lineage pathway (pro-B) (7) , defined as cells that express the B220 surface marker and give rise to B lineage but not T lineage cells (6) . Pro-B can be divided into three stages [designated Fractions (Fr.) A, B, and C by Hardy and colleagues (2) In adult BM, the surface markers that distinguish pro-B cells from cells at later stages of B cell development include B220 levels, CD4, CD43, BP-1, CD24, IgM, IgD, and MHC class II (Ia). Of these, only B220 and CD4 are expressed on germ-line pro-B cells. B220 is expressed at low or intermediate levels on all of these cells, whereas CD4 is expressed on a major subset (which expresses B220 at intermediate levels). The ability of the CD4 ϩ subset to give rise to B cells has recently been brought into question by evidence showing that these cells fail to develop into B cells in vitro under conditions that readily allow B cell development from germ-line pro-B that do not express CD4 (9, 10) . Studies here, however, show that both subsets express roughly equal amounts of mRNA encoding traditional pro-B cell markers-i.e., sterile , TdT, Ig␤ (CD79b)-and hence indicate that both subsets contain B cell progenitors.
Studies here also show that MHC Class II (Ia) marks most of the cells in the CD4 ϩ germ-line pro-B cells subset and is marginally detectable (very low levels) on CD4 Ϫ germ-line pro-B cells. These findings confirm and extend earlier work documenting Ia expression during B cell development. Fluorescenceactivated cell sorter (FACS) studies completed shortly after monoclonal anti-Ia reagents were developed initially indicated that Ia is expressed only on mature B cells (11) . However, more recent studies show that Ia is also expressed on pre-B cells in adult BM, albeit at roughly 30% the level expressed on mature splenic B cells (12, 13) . In addition, evidence from functional studies indicates that Ia expression begins even earlier in B cell development, because the generation of pre-B cells from progenitor cells in adult BM is blocked either by culturing progenitors in the presence of anti-Ia monoclonal antibody or by expressing antisense RNA in the progenitors (14) .
These findings with adult BM contrast with evidence demonstrating that Ia is not expressed on pre-B cells in fetal and neonatal animals (1, 12, 13) . In fact, several studies show that Ia expression cells in the B cell development pathway in fetal and neonatal mice only begins when cells reach the immature B cell stage, identifiable by the expression of surface IgM in the absence of IgD (12, 13) . Our findings confirm these earlier findings and add that Ia is not expressed on germ-line pro-B in the fetal and neonatal animals. In addition, we explain these findings by showing that the CD4 ϩ germ-line pro-B subset that contains the Ia ϩ pro-B cells in adults is not present in the fetal͞neonatal animals. In essence, we show that the only germ-line pro-B cells present in fetal͞neonatal animals express essentially the same phenotype as the minor subset of germ-line pro-B cells in adults-i.e., very low levels of B220, no detectable CD4, and marginal or undetectable Ia.
We discuss this key difference between the adult and fetal͞ neonatal B cell development pathways in the context of whether B-1 cells, which primarily develop in fetal and neonatal animals, arise from the same progenitors as B-2 cells, which primarily develop in adult BM. Basically, our findings distinguish the fetal͞neonatal and adult B cell developmental pathways at a very early stage and thus favor distinctive origins for B-1 and B-2 cells.
Materials and Methods
Mice and Cell Preparation. BALB͞c, C57BL͞6, gene targeted disruption of chain (MT) mice (15) from The Jackson Laboratory, RAG2-deficient mice (RAG2 Ϫ/Ϫ ) (16) obtained from Weissman laboratory at Stanford, and C3H and GFP-Tg mice were bred and maintained at the Animal Facility at Stanford University. BM and spleen cells were harvested from adults (8-12 weeks of age; liver cells were harvested from mouse fetus at timed points (the appearance of the vaginal plug was designed as day 0 of gestation) and from neonates day 2-10 after birth. Single-cell suspensions were prepared in ''staining medium'' (biotin-and flavin-deficient RPMI medium 1640, supplemented with 5% FCS). 2), CD43 (S7). Antibodies and fluorochrome conjugates were either prepared at Stanford or obtained from PharMingen. Streptavidin-Cy5-PE and streptavidin-Texas red (TR) from BD PharMingen were used as second-step reagents. Noncommercial conjugates and tandem dyes were prepared as described (17) . FITC, Alexa-594, Cascade Blue, and Cascade Yellow were obtained from Molecular Probes. Cy5, Cy5.5, and Cy7 were obtained from Amersham Pharmacia Life Science (Pittsburgh).
11-Color
To determine the level of nonspecific staining and autofluorescence associated with cells in each fluorescence channel, cells were stained with each mixture of reagents with one reagent omitted at a time to create a ''standard staining control'' for each channel. Cell samples were also stained with single fluorochrome-coupled reagents to obtain data for fluorescence compensation for each fluorochrome. Propidium iodide (PI) was added to all samples before data collection to enable identification of dead cells. Data were collected on Hi-D FACS, a modified triple laser FACStarPlus (Becton Dickinson) connected to MoFlo electronics (Cytomation͞Becton Dickinson hybrid FACS, Cytomation, Fort Collins, CO) by FACS͞DESK software as described (17, 18) . Finally, data cataloged and stored with FACS͞DESK (Stanford) were transferred to Flowjo (Tree Star, San Carlos, CA) for fluorescence compensation and analysis. Hi-D FACS was also used to sort cells stained as above. Sorted cells were reanalyzed immediately after sorting; purities were Ͼ99%.
Reverse Transcription (RT)-PCR Analyses. MHC class II (Ia).
Total RNA was extracted from FACS-sorted B-lineage subsets (for definition, see Figs. 1 and 7) and CD4 ϩ T lymphocytes by using TRI-Reagent (Molecular Research Center, Cincinnati) according to the procedures recommended by the manufacturer. Firststrand cDNA was synthesized from 1 g of total RNA by using Superscript RT and random hexamers (Life Technologies and GIBCO). The resulting cDNA was amplified with gene-specific primers for ␤-actin, I-A␣, I-A␤, I-E␣, and I-E␤ (synthesized by The Protein and Nucleic Acid Facility at Stanford University) as reported (9) and subjected to 30 PCR cycles (2400 Gene Amp Thermal Cycler, Perkin-Elmer). Each cycle consisted of denaturing at 95°C for 30 s, annealing at 58°C for 30 s, and polymerizing at 72°C for 45 s. Amplification of the ␤-actin gene was used throughout as a control for template intensity and for normalization of data to a constitutively expressed transcripts.
TdT, Ig␤, sterile ( 0 ), and Ia␤. ⌻he RT-PCR protocols described above, with the following modifications, were used to obtain data in Fig. 5 . Total RNA was extracted from 4.5 ϫ 10 4 sorted cells by using TRI-Reagent. After ethanol precipitation, the RNA pellet was resuspended in 5 l of diethyl pyrocarbonate (DEPC)-treated water and used for first-strand cDNA synthesis. After addition of 1 l of 50 ng͞ml of random hexamers and 1 l of 10 mM dNTP in a 10-l volume, the reaction was incubated at 65°C for 2 min and placed on ice. The following reagents were then added: 2 l of 10ϫ RT buffer (GIBCO͞BRL); 4 l of 25 mM MgCL 2 ; 2 l of 0.1 M DTT; 1 l of RNase inhibitor (Promega); and 1 l of 200 units͞l Superscript RTII (GIBCO͞ BRL). The reaction was incubated at 42°C for 2 h and heated at 72°C for 10 min. The reactions were stored at Ϫ20°C until PCR amplification.
cDNA was amplified using different sets of gene-specific PCR primers (kindly supplied by R. R. Hardy, Fox Chase Cancer Center, Philadelphia) (4). PCR analyses were performed in a 50-l volume containing 1 l of cDNA sample, 1ϫ PCR reaction buffer, 200 M of dNTP, 1 M of primer sets, and 5 units of Taq polymerase (GIBCO͞BRL). The PCR reactions were carried out using the following conditions: 94°C for 40 s; annealing at 62°C for 40 s for the first five cycles and at 60°C for 40 s for the following cycles; polymerization at 72°C for 40 s. Aliquots were withdrawn between 36 and 40 cycles to ensure that the amplification is within the linear range. The housekeeping gene, ␤-actin, was also amplified as positive controls. Five microliters of the PCR products was separated by 1.2% agarose gel electrophoresis and visualized using ethidium bromide.
PCR Assay for Detection of IgH Gene Rearrangements. For PCR analysis of Ig gene D H J H rearrangement, the genomic DNA was extracted from the same FACS-sorted populations and FLST2 cells as those described above by using TRI-reagent (Molecular Research Center, Cincinnati) according to the manufacturer's instructions. DNA quantity and quality were determined by OD scanning. One microgram of DNA from each sample was amplified for detection of Ig heavy-chain D H J H and V H D H J H rearrangement by PCR. Gene-specific primers, including the primer for the ␤-actin gene, have been described (19) . PCRs consist of 30 cycles (1 min at 94°C, 1 min at 60°C, and 1.5 min at 72°C). Each PCR was followed by 10-min incubation at 72°C. In essence, we sequentially exclude most of the cells in BM by using propidium iodide to exclude dead cells and a mixture of reagents (dump1: CD3, CD8, F4͞80, and Gr-1 marked with Cascade blue) to identify and gate out cells that do not belong to the B cell lineage. Next, we use a second mixture (dump2: BP-1, IgM, IgD, CD19, and CD24 marked with FITC) to identify all B lineage cells that have matured to Hardy Fr. B or beyondi.e., that express markers indicative of progression to IgH rearrangement. We then plot dump2 versus B220 and display the resulting figure as a contour plot (Fig. 1) and draw a gate that includes the B220 ϩ dump2Ϫ population.
Results

Identification of Germ
This gating scheme enables unambiguous exclusion of the more mature (dump2 ϩ ) B lineage cells and thereby makes it possible to obtain a discrete population of germ-line pro-B cells (Fig. 1) . Importantly, it allows the B220 gate to be set to include cells that express very low B220 levels. As studies that follow demonstrate, these cells belong to an important germ-line pro-B subset that is poorly represented in adults but constitutes the only pro-B subset detectable in neonatal animals.
PCR analysis of IgH rearrangement status in FACS-sorted germ-line pro-B identified as above confirms the lack of IgH rearrangement in cells in this fraction. To assess D H J H rearrangement, we used a set of primers that amplifies a ladder of rearranged D H J H fragments-i.e., an oligonucleotide primer pair that can amplify 10͞12 of the D H segments and a primer complementary to a segment of DNA 3Ј of J H 4. Using these primers, PCR analyses of DNA prepared from FACS-sorted germ-line pro-B and from Hardy Frs. A-F, show that the IgH genes in the germ-line pro-B and the Hardy Fr. A are in germ-line configuration whereas the IgH loci in Frs. B and C have significant D H J H recombination (Fig. 2) . (Fig. 3) . Two major subsets appear: a CD4 ϩ subset that expresses relatively higher levels of B220 (although not as high as the levels on mature B cells); and a CD4 Ϫ subset that expresses very low B220 levels. By ignoring the small percentage of cells that fall into the overlapping region between the subsets (CD4 Ϫ , relatively bright B220), boundaries for each of the two clearly distinguishable subsets can be drawn to include nearly all of the cells in the subset with little contamination from the other (Fig. 3) .
The pro-B subsets visualized in Fig. 3 are present both in wild-type mice and in gene-targeted mice in which B cell development terminates at the pro-B cell stage (RAG2 Ϫ/Ϫ ) (Fig.  4) (15, 16) . However, the RAG2 CD4 ϩ population appears to be further subdivided, suggesting that the differentiation block in these animals results in the accumulation of cells that are not visible as a separate subset when differentiation proceeds normally. This subdivision of the CD4 ϩ pro-B cells in the RAG2 mice merits further study. Of importance here, the data in the In previous studies, pre-B cells in adult BM were shown to express Ia whereas Ia was not detected on pro-B cells (12, 13) . However, the increased discrimination enabled by Hi-D FACS analysis enables detection of Ia expression at low levels on cells in the CD4 ϩ germ-line pro-B subset (Fig. 6 ). Roughly half of the cells in this subset express Ia, whereas there is only marginal Ia expression on cells in the CD4 Ϫ subset. In contrast, the CD4 Ϫ subset includes 10-15% of cells that express CD11b, whereas this marker is not detectable on the CD4 ϩ subset (Hi-D FACS data not shown). Several other early pro-B cell markers are expressed equally in both subsets-i.e., CD117 (c-kit), CD127 (IL-7R␣), and AA4.1 (Hi-D FACS data not shown).
Interestingly, the quantitative expression of Ia changes dramatically during B cell development. The median Ia expression level detected by Hi-D FACS on CD4 ϩ pro-B cells is roughly 3-fold lower than the Ia level on pre-B cells and fully 10-fold lower than the Ia level on mature B cells (Fig. 7) . Nevertheless, the amount of Ia expressed on CD4 ϩ pro-B cells is clearly above controls levels, defined as the background fluorescence detected for cells stained with all reagents except the anti-Ia (see Materials and Methods). The ''marginal'' Ia expression on the CD4 Ϫ subset, in contrast, is barely above background and difficult to ascertain. Although we detect a small amount of Ia mRNA in the sorted CD4 Ϫ pro-B cell fraction, we cannot rule out contaminating cells (Fig. 5) . Therefore, we define the Ia expression in this fraction as marginal an await further studies to resolve this issue. This trend is reversed later in development (Frs. D-F). Our data (not shown) confirm previous findings (12) demonstrating that the majority of pre-B cells express Ia and the frequency of Ia ϩ cells increases progressively, from 60 to 100%, as cells develop from pre-B to mature B cells. In addition, we confirm that the amount of Ia expressed per cell increases during maturation from pre-B to B. Thus, overall, Ia levels increase from the low levels detectable on pro-B cells to intermediate Ia expression has also been shown to distinguish later stages of B cell development in neonates and adults. That is, Ia is detectable on pre-B and later stages in the adult B cell development pathway but is not detectable on B lineage cells in fetal and neonatal animals until developing B cells express surface Ig and are close to maturity (12, 13) . Our data extend these earlier findings by showing that Ia is expressed at lower but clearly detectable levels on the CD4 ϩ subset of adult pro-B cells, beginning at the earliest stage of pro-B cells development, but that this subset is missing in neonates.
Ia Expression Continues
These findings are consistent with a two-lineage B cell development model, because B-1 cells (mainly B-1a) are the principal outcome of B cell development in fetal and neonatal animals, whereas B-2 cells and some B-1 cells (mainly B-1b) are the products of B cell development in adults. In a simple model consistent with this evidence, the CD4 ϩ germ-line pro-B could be seen as progenitors of B-2 cells, whereas the CD4 Ϫ germ-line pro-B could be seen as progenitors of B-1a cells in neonates and of B-1b and perhaps marginal zone cells in adults.
